CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer (MRD)

Location: Edward Cancer Center - Naperville
Edward Cancer Center - Plainfield
Nancy Knowles Cancer Center - Elmhurst

Purpose:

The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for a minimum of 3 years and up to 5 years for recurrence.

Sponsor: Exact Sciences Corp./NSABP

https://clinicaltrials.gov/ct2/show/NCT05210283

Eligibility:

• Histologic diagnosis of carcinoma of the colon or rectum
• Undergone complete surgical resection of the primary tumor within 3 months prior to enrollment.
• Pathologic stage II or III
• No clinical contraindication to adjuvant chemotherapy.
• No prior systemic anti-cancer therapy.
• No prior history and treatment for any invasive cancer within the past 5 years, with the exception of non-melanoma skin cancer

Time Commitment: 3-5 years